Table 1.

Baseline clinical and demographic characteristics of patients from each of the four clinical trial cohorts.

	Nivolumab (CheckMate 238)	Nivolumab (CheckMate 915)	Ipilimumab	Ipilimumab plus nivolumab
N	157	190	408	195
Age (years)
Mean (SD)	55.11 (14.00)	56.39 (12.92)	53.85 (13.35)	56.39 (12.92)
Sex
Female	68 (43.3%)	80 (42.1%)	169 (41.4%)	89 (45.6%)
Male	89 (56.7%)	110 (57.9%)	239 (58.6%)	106 (54.4%)
Race
White	153 (97.5%)	189 (99.5%)	391 (95.8%)	191 (97.9%)
Asian	4 (2.5%)	1 (0.5%)	16 (3.9%)	0 (0.0%)
Disease stagea
IIIB	64 (40.8%)	58 (30.5%)	137 (33.6%)	50 (20.6%)
IIIC	60 (38.2%)	97 (51.1%)	190 (46.6%)	111 (56.9%)
IIID	0 (0.0%)	8 (4.2%)	0 (0.0%)	8 (4.1%)
IV	31 (19.7%)	27 (14.2%)	81 (19.9%)	26 (13.3%)
BRAF mutation status
Wild-type	73 (46.5%)	93 (48.9%)	190 (46.6%)	85 (43.6%)
Mutant	66 (42.0%)	53 (27.9%)	174 (42.6%)	66 (33.8%)
Not reported	18 (11.5%)	44 (23.2%)	44 (10.8%)	44 (22.6%)
Baseline ECOG
0	140 (89.2%)	183 (96.3%)	363 (89.0%)	181 (92.8%)
1	17 (10.8%)	7 (3.7%)	45 (11.0%)	14 (7.2%)
Baseline LDH (U/L)
Mean (SD)	225.38 (97.52)	208.69 (64.23)	215.19 (88.36)	223.15 (81.85)
PD-L1 status
<5%	94 (59.9%)	147 (77.4%)	253 (62.0%)	142 (72.8%)
≥5%	56 (35.7%)	43 (22.6%)	143 (35.0%)	53 (27.2%)
Not reported	7 (4.5%)	0 (0.0%)	12 (2.9%)	0 (0.0%)
Disease recurrence
No	99 (63.1%)	129 (67.9%)	190 (46.6%)	121 (62.1%)
Yes	58 (36.9%)	61 (32.1%)	218 (53.4%)	74 (37.9%)
Severe toxicity
No	93 (59.2%)	148 (77.9%)	202 (49.5%)	131 (67.2%)
Yes	64 (40.8%)	42 (22.1%)	206 (50.5%)	64 (32.8%)

^aPatients in CheckMate 238 were staged using the AJCC Staging Manual 7th Edition. Patients in CheckMate 915 were staged using the AJCC Staging Manual 8th Edition.